JP2023509964A - 真核生物翻訳可能ｍＲＮＡの生成および真核生物への送達のための微生物システム - Google Patents

真核生物翻訳可能ｍＲＮＡの生成および真核生物への送達のための微生物システム Download PDF

Info

Publication number
JP2023509964A
JP2023509964A JP2022542207A JP2022542207A JP2023509964A JP 2023509964 A JP2023509964 A JP 2023509964A JP 2022542207 A JP2022542207 A JP 2022542207A JP 2022542207 A JP2022542207 A JP 2022542207A JP 2023509964 A JP2023509964 A JP 2023509964A
Authority
JP
Japan
Prior art keywords
eukaryotic
mrna
translatable
translatable mrna
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022542207A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509964A5 (https=
Inventor
リンケ，リンジー，エム．
ウィリアムズ，アシュリー，ビー．
モラ，ダーシー
コックス，マデリン
Original Assignee
シベック バイオテクノロジーズ エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シベック バイオテクノロジーズ エルエルシー filed Critical シベック バイオテクノロジーズ エルエルシー
Publication of JP2023509964A publication Critical patent/JP2023509964A/ja
Publication of JP2023509964A5 publication Critical patent/JP2023509964A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/101—Plasmid DNA for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/60—Vectors comprising a special translation-regulating system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022542207A 2020-01-11 2021-01-11 真核生物翻訳可能ｍＲＮＡの生成および真核生物への送達のための微生物システム Pending JP2023509964A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062959976P 2020-01-11 2020-01-11
US62/959,976 2020-01-11
US202063118593P 2020-11-25 2020-11-25
US63/118,593 2020-11-25
PCT/US2021/012992 WO2021142458A1 (en) 2020-01-11 2021-01-11 A microbial system for production and delivery of eukaryote-translatable mrna to eukarya

Publications (2)

Publication Number Publication Date
JP2023509964A true JP2023509964A (ja) 2023-03-10
JP2023509964A5 JP2023509964A5 (https=) 2024-01-18

Family

ID=76788329

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542207A Pending JP2023509964A (ja) 2020-01-11 2021-01-11 真核生物翻訳可能ｍＲＮＡの生成および真核生物への送達のための微生物システム

Country Status (8)

Country Link
US (1) US20210222178A1 (https=)
EP (1) EP4087934A4 (https=)
JP (1) JP2023509964A (https=)
KR (1) KR20220150276A (https=)
CN (1) CN115335527A (https=)
AU (1) AU2021206307A1 (https=)
CA (1) CA3164395A1 (https=)
WO (1) WO2021142458A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
MX362981B (es) 2012-03-27 2019-02-28 Curevac Ag Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
SG10201913630YA (en) 2016-02-17 2020-03-30 Curevac Ag Zika virus vaccine
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
IL300447A (en) * 2020-08-12 2023-04-01 Actym Therapeutics Inc Bacteria-based ingredients that stimulate the immune system, treatments and platforms for delivering RNA
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
AU2022286964A1 (en) * 2021-06-02 2024-01-18 Sivec Biotechnologies Llc Bacterial delivery of antibodies, antibody derivatives, and polypeptides to eukaryotic cells
CN114507691A (zh) * 2022-03-02 2022-05-17 深圳市瑞吉生物科技有限公司 一种用于制备环状rna的载体及其应用
CN114622020B (zh) * 2022-03-30 2022-09-27 华南农业大学 一种与鸡生长性状相关的klhl31基因分子标记及应用
EP4608442A1 (en) 2022-10-28 2025-09-03 GlaxoSmithKline Biologicals S.A. Nucleic acid based vaccine
CN120400199A (zh) * 2024-01-31 2025-08-01 上海缮维特生物技术有限公司 一种真核表达载体、包含其的细菌及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001519162A (ja) * 1997-10-07 2001-10-23 ユニバーシティ・オブ・メリーランド・バイオテクノロジー・インスティチュート 動物細胞にｒｎａを導入して発現させる方法
JP2016521133A (ja) * 2013-05-15 2016-07-21 クルーゼ，ロバート 環状ｒｎａの細胞内翻訳
WO2018187381A2 (en) * 2017-04-03 2018-10-11 Sivec Biotechnologies, Llc A transkingdom platform for therapeutic nucleic acid delivery
WO2020010344A1 (en) * 2018-07-04 2020-01-09 Pebble Labs Usa, Inc. System and methods for engineering bacteria fit for eukaryotic mrna production, export, and translation in a eukaryotic host

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1820020B (zh) * 2003-05-06 2010-04-28 技术持有有限公司 Sars-冠状病毒病毒样颗粒以及应用方法
PL2922554T3 (pl) * 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
WO2018185564A2 (en) * 2017-04-07 2018-10-11 Uti Limited Partnership Assay to measure the potency of receptor-ligand interactions in nanomedicines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001519162A (ja) * 1997-10-07 2001-10-23 ユニバーシティ・オブ・メリーランド・バイオテクノロジー・インスティチュート 動物細胞にｒｎａを導入して発現させる方法
JP2016521133A (ja) * 2013-05-15 2016-07-21 クルーゼ，ロバート 環状ｒｎａの細胞内翻訳
WO2018187381A2 (en) * 2017-04-03 2018-10-11 Sivec Biotechnologies, Llc A transkingdom platform for therapeutic nucleic acid delivery
WO2020010344A1 (en) * 2018-07-04 2020-01-09 Pebble Labs Usa, Inc. System and methods for engineering bacteria fit for eukaryotic mrna production, export, and translation in a eukaryotic host

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S.UMEKAGE, ET AL., JOURNAL OF BIOSCIENCE AND BIOENGINEERING, vol. 108, no. 4, JPN6024053298, 2009, pages 354 - 356, ISSN: 0005717327 *

Also Published As

Publication number Publication date
WO2021142458A1 (en) 2021-07-15
EP4087934A4 (en) 2024-03-13
KR20220150276A (ko) 2022-11-10
EP4087934A1 (en) 2022-11-16
US20210222178A1 (en) 2021-07-22
CA3164395A1 (en) 2021-07-15
CN115335527A (zh) 2022-11-11
AU2021206307A1 (en) 2022-09-08

Similar Documents

Publication Publication Date Title
JP2023509964A (ja) 真核生物翻訳可能ｍＲＮＡの生成および真核生物への送達のための微生物システム
US10927383B2 (en) Cas9 mRNAs
EP2996697B1 (en) Intracellular translation of circular rna
CN111492056B (zh) 用于细胞的遗传修饰的非整合型dna载体
US20230061936A1 (en) Methods of dosing circular polyribonucleotides
CN106434725B (zh) 小环dna载体制剂及其制备方法和使用方法
CN115151277A (zh) 负载核酸的红细胞细胞外囊泡
CN115768487A (zh) 用于面肩肱型肌营养不良症的crispr抑制
JP2021522849A (ja) メッセンジャーｒｎａキャップのその５’末端に導入された２つのｒｎａ配列での置換
US20240000914A1 (en) Chicken anemia virus (cav)-based vectors
US20230348933A1 (en) Tandem anellovirus constructs
US20230227849A1 (en) Methods of identifying and characterizing anelloviruses and uses thereof
WO2024083095A1 (zh) 环状rna及载体和载体的应用
US20250171806A1 (en) Engineered viral vectors with enhanced packaging capacity and methods of using the same
KR20260022409A (ko) 발현 조절이 가능한 엔지니어링된 rna 분자
JPWO2019117057A1 (ja) 細胞膜透過性ペプチド
WO2024139837A1 (en) Recombinant nucleic acids, kits comprising the same, and uses thereof in treating coronavirus infection
CN120168624B (zh) 一种伪狂犬免疫原组合物及其用途
EP4495243A1 (en) Novel method for producing exosome containing target nucleic acid and serving as nucleic acid medicine
WO2025045247A1 (en) Nucleic acids encoding crispr-associated proteins and uses thereof
WO2025247180A1 (zh) 用于制备含较少非目的序列的环状rna的载体和方法
HK40114401A (zh) 用於基因组编辑的多核苷酸、组合物和方法
HK40082089A (en) Nucleic acid loaded red blood cell extracellular vesicles
WO2026017063A1 (zh) 用于制备不含非目的序列的环状rna的载体和方法
CN118660960A (zh) 用于基因组编辑的多核苷酸、组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240110

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250403

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250704

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251028